Beranda › Nefritis Lupus › Colorado
Uji klinis Nefritis Lupus di Colorado
7 studi untuk Nefritis Lupus mencari peserta di lokasi di Colorado.
Kota di Colorado
Teks studi resmi (Bahasa Inggris)
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
- University of Colorado Denver, Aurora
Menerima pesertaFase 2
Usia 18 hingga 100 · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT05268289VIBRANT: VIB4920 for Active Lupus Nephritis
- University of Colorado School of Medicine: Division of Rheumatology, Aurora
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT05201469The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study
- Children's Hospital Colorado, Aurora
Menerima pesertaFase 2
Usia 8 hingga 20 · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT05538208A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- University of Colorado Denver, Aurora
Menerima pesertaFase 1
Usia 18 hingga 74 · Semua jenis kelamin · Diperbarui 10 Sep 2026 · NCT07085104A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
- Children's Hospital Colorado, Anchutz Medical Campus, Aurora
Menerima pesertaFase 2
Usia 5 hingga 17 · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT05039619PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis
- Western Nephrology & Metabolic Bone Disease, PC, Arvada
Menerima pesertaFase 4
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 3 Agu 2026 · NCT07611214A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
- University of Colorado, Denver, Denver
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Feb 2026 · NCT07403188Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.